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1. Introduction  
Breast cancer is one of the most common and serious malignancies worldwide. Despite 
intensive cancer control efforts, it remains the second-leading cause of cancer death among 
women (Harris et al., 2000). While the overall response rate can be high, the duration of 
response is relatively short, and most patients with initially responsive tumors will 
experience a drug-resistance phenotype. Therefore, a lot of studies have centered on the 
field of drug resistance to improve cancer chemotherapy and management of cancers 
Gottesman, 2002). 
The development of intrinsic or acquired resistance to a wide variety of anticancer drugs is a 
major obstacle to successful cancer chemotherapy. Some cancers show primary resistance or 
natural resistance in which they do not respond to standard chemotherapy drugs from the 
beginning. On the other hand, many types of sensitive tumors respond well to 
chemotherapy drugs in the beginning but show acquired resistance later (Choi, 2005). 
Multidrug resistance (MDR) can be defined as the intrinsic or acquired resistance of cancer 
cells to multiple classes of structurally and mechanistically unrelated antitumor drugs 
(Teodori et al., 2002). To date, the most widely studied cellular mechanisms of MDR are 
those associated with drug efflux involving members of the adenosine triphosohate-binding 
cassette (ABC) membrane transporter family (Mao et al., 2005).  
Recently, several human ABC transporters with a potential role in drug resistance have been 
discovered. Among them, a novel known protein is ATP-binding cassette sub-family G 
member 2 (ABCG2). Human ABCG2 (also known as MXR, BCRP, and ABCP) was first cloned 
by Doyle et al. (Doyle et al., 1998) in the drug-resistant breast cancer cell line (MCF-7). ABCG2 
is an efflux pump, which transports a variety of xenobiotics and endogenous compounds 
across cellular membranes. Tissue localization of ABCG2 in the mammary glands, intestine, 
kidney, liver, ovary, testis, placenta, endothelium and in hematopoietic stem cells indicates 
that ABCG2 plays an important role in absorption, distribution, and elimination of its 
substrates (Krishnamurthy et al., 2004; Mao & Unadkat, 2005). The expression of ABCG2 
protein and/or mRNA has been detected in numerous types of human cancers (Diestra et al., 
2002; Ross et al., 2000), and a large spectrum of anticancer drugs are effluxed by ABCG2 
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(Doyle et al., 2003). It has also been shown that ABCG2 expression may be associated with 
poor response to chemotherapy (van den Heuvel-Eibrink et al., 2002, Steinbach, 2002 #216) . 
Alteration in ABCG2 expression and function can significantly affect the disposition of the 
transporter drug substrates, it is possible that its overexpression in cancer cells is responsible 
for decreasing in drug concentration within the cell and a reduced cancer-chemotherapy 
efficacy (Glavinas et al., 2004; Mao & Unadkat, 2005).  
Inflammation is a state consisting of complex cytological and chemical reactions that occur 
in affected blood vessels and adjacent tissues in response to an injury or abnormal 
stimulation caused by physical, chemical or biological agents (Ho et al., 2006; Philip et al., 
2004). Although inflammation is essential, it can be harmful to the host and therefore it is 
subject to multiple levels of biochemical, pharmacological, and molecular controls involving 
a diverse and potentially huge array of cell types and soluble mediators including cytokines 
(Haddad, 2002). In fact tumors are similar to healing or desmoplastic tissue in many ways 
and the micro-environment of the tumor highly resembles an inflammation site (Caruso et 
al., 2004). Breast cancer is a prototype of these kinds of cancer. Indeed, proinflammatory 
cytokines have been found to be present within the microenvironment of breast carcinomas 
and secreted by infiltrating host leukocytes, malignant and/or stromal cells of the breast 
cancer (Basolo et al., 1996; Jin et al., 1997; Lithgow et al., 2005; Miles et al., 1994).  
In recent years, it has been demonstrated that the expression and function of the MDR 
transporters is altered in numerous tissues during an inflammatory response. The current 
review focuses on the elucidation of the effects of inflammation on the ABCG2 expression 
and function, using MCF-7 human breast carcinoma cell line. 
2. The role of inflammation on the ABCG2 expression and function  
In an overview, the results of several studies on the effect of inflammation on the levels of 
ABCG2 protein expression and function in MCF-7 cells will be reviewed in this paper. In the 
first part, the observed effects of the proinflammatory cytokines on the ABCG2 protein 
expression and function will be expressed. In the next section, the effects of cyclooxygenase 
2 on drug resistance due to ABCG2 will be reviewed and eventually the influence of 
treatment with anti-inflammatory drugs indomethacin and dexamethasone on the incidence 
of drug resistance phenotype will be expressed.  
2.1 Proinflammatory cytokines and ABCG2 expression and function  
Proinflammatory cytokines including interleukin-1ǃ (IL-1ǃ), interleukin-6 (IL-6) and tumor 
necrosis factor-ǂ (TNF-ǂ) are well-known regulators of inflammatory response. 
Inflammatory components including host leukocytes, chemokines and cytokines are also 
present in the microenvironment of most probably all tumors including those not casually 
related to an obvious inflammatory process (Germano et al., 2008).  
Numerous in vitro and in vivo investigations reported that inflammation and 
proinflammatory cytokines are able to modulate the expression or function of different drug 
transporters including Multi-Drug Resistance transporter 1 (MDR1/ABCB1), Multidrug 
Resistance-associated Proteins (MRPs/ABCCs) and Lung-resistance Related Protein / Major 
Vault Protein (LRP/MVP). These modulations appeared to happen at various levels of 
expression including transcriptional, posttranscriptional, translational, and/or post-
translational levels (Bertilsson et al., 2001; Hartmann et al., 2002; Hirsch-Ernst et al., 1998; 
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Piquette-Miller et al., 1998; Stein et al., 1997; Sukhai et al., 2001; Theron et al., 2003; Vos et al., 
1998; Walther et al., 1994; Walther et al., 1995). 
The influence of proinflammatory cytokines (IL-1ǃ, IL-6 and TNF-ǂ) on ABCG2 expression 
and function in human MCF-7 breast cancer cell line were studied using real-time PCR and 
flow cytometry, respectively. The results showed that, the levels of ABCG2 mRNA, protein 
expression and function in MCF-7 cells increased significantly after treatment with either IL-
1ǃ or TNF-ǂ (Fig. 1).  
 
 
     
Fig. 1. The effects of proinflammatory cytokines on ABCG2 mRNA expression (A) and 
protein levels (B) in MCF-7 cells.  
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A;Cells were treated with 10 ng/ml of each cytokine for 12–72 h and real-time RT-PCR 
analysis was performed on total RNA extracted from control and treated cells. Values were 
normalized to the ǃ-actin content of samples and expressed as mean (% control) ±SD (n = 3); 
*P<0.05; **P<0.01 versus control (0 ng/ml). B; After 72-h incubations with IL-1ǃ (50 ng/ml), 
IL-6 (50 ng/ml) or TNF-ǂ (50 ng/ml), expression of ABCG2 protein was measured by flow 
cytometry. Each value represents MFI mean (% control) of at least three independent 
experiments ± SD; *P<0.05, **P<0.01 versus controls. 
Pradhan and colleagues also found that under proinflammatory conditions two 
transcription factors, estrogen receptor (ER) and NF-κB are cooperatively recruited to the 
promoter region of the ABCG2 gene at adjacent sites. ER allows the NF-κB family member 
p65 to access a latent NF-κB response element located near the estrogen response element 
(ERE) in the gene promoter; in turn, this p65 recruitment is required to stabilize ER 
occupancy at the functional ERE. Once present together on the ABCG2 promoter, ER and 
p65 act synergistically to potentiate mRNA and subsequent protein expression. This study 
has important implications for patients with ER-positive breast tumors, as it reveals a 
mechanism whereby inflammation enhances the expression of an ER target gene, which in 
turn can exacerbate breast tumor progression by promoting drug resistance mechanism 
whereby inflammation enhances the expression of an ER target gene, which in turn can 
exacerbate breast tumor progression by promoting drug resistance (Pradhan et al., 2010). 
On the other hand, while IL-6 had no significant effects on ABCG2 mRNA expression and 
function in MCF-7 cells, it could slightly increase ABCG2 protein expression in these cells. 
This shows that IL-6 probably modulates ABCG2 expression by affecting ABCG2 protein 
translation and/or stability, but not ABCG2 transcription. For unknown reasons, this 
modulation did not result in the increased activity of the protein (Mosaffa et al., 2009).  
In contrast to the results obtained for MCF-7 cells, in its mitoxantrone-resistance derivative, 
MCF-7/MX cells, none of the cytokines (even at high concentrations and long incubation 
times) exerted significant effects on ABCG2 mRNA levels. Because MCF-7/MX cells 
overexpress ABCG2 mRNA, it is likely that although modulation of the signaling 
pathway(s) responsible for increased transcription of ABCG2 in IL-1ǃ and TNF-ǂ-treated 
MCF-7 cells, has already happened in MCF-7/MX cells, but treatment with these cytokines 
could not cause further induction in ABCG2 mRNA levels (Mosaffa et al., 2009). 
The results showed that IL-1ǃ increased ABCG2 function and TNF-ǂ enhanced both ABCG2 
protein expression and function in MCF-7/MX cells. This lack of correspondence between 
mRNA and expression/function data suggests that perhaps in addition to the 
transcriptional regulatory effects of IL-1ǃ and TNF-ǂ, these two cytokines can also mediate 
ABCG2 expression and function via translational and/or post-translational effects (Mosaffa 
et al., 2009).  
2.2 Cyclooxygenase-2 and ABCG2 expression and function  
Cyclooxygenases (COX), also known as prostaglandin endoperoxide synthases or 
prostaglandin H synthases, comprise a group of enzymes that participate in the conversion 
of arachidonic acid to prostaglandins (PGs) that affect a number of physiological and 
pathological states in neoplastic and inflamed tissues (Smith et al., 1996). There are two 
isoforms of the enzyme that have been identified, COX-1 and COX-2. Constitutively 
expressed COX-1 supplies normal tissues with prostaglandins required to maintain 
physiological organ functions (O'Neill et al., 1993), such as cytoprotection of the gastric 
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mucosa (Chan et al., 1995) and regulation of renal blood flow (Tanioka et al., 2003). On the 
other hand, COX-2 is highly induced by growth factors (epidermal growth factor (EGF)), 
cytokines (IL-1ǃ, IL6, TNF-ǂ (Davies et al., 2002; Zhang et al., 2006)), and carcinogens 
(phorbol esters (Liu et al., 1996; Rigas et al., 2005)) via protein kinase C (PKC) and RAS-
mediated signaling at sites of inflammation. Therefore, it is assumed that COX-2 plays an 
important role in the prostaglandin E2 (PGE2) production involved in pathophysiological 
processes (Trebino et al., 2003). COX-2 may be implicated in tumor promotion through 
modulating cell proliferation, inhibiting apoptosis, control of cell migration, cell adhesion, 
tumor invasion and suppression of immune response (Cao et al., 2002). In recent years, it 
has been reported that COX-2 modulates ABC transporter expression and is involved in the 
development of the MDR phenotype (Ratnasinghe et al., 2001, Fantappiè O, 2002 #78, 
Puhlmann, 2005 #103). 
Kalalinia et al. studies had aimed to explore the potential link between COX-2 expression 
and development of multidrug resistance phenotype due to ABCG2 expression in MCF-7 
cell line. In one study they used of 12-O-tetradecanoylphorbol-13-acetate (TPA) for 
induction of COX-2 expression in MCF-7 cells. TPA often employed in biomedical research 
to activate the signal transduction enzyme protein kinase C (PKC). The effects of TPA on 
PKC result from its similarity to one of the natural activators of classic PKC isoforms, 
diacylglycerol (DAG).  
 
 
Fig. 2. Effects of TPA on the levels of ABCG2 mRNA in MCF-7 cells. 
Cells were treated with TPA (0-100 nM for 4-48 h) and ABCG2 mRNA expression was 
measured by real-time RT-PCR using total RNA extracted from control and treated cells. 
Relative expression levels for each gene were normalized to that of the ǃ-actin. The results 
were expressed as: (target/reference ratio) treated samples / (target/reference ratio) 
untreated control sample. Values were expressed as mean ± SD (n = 3); *, p < 0.05; **, p < 
0.01; ***, p < 0.001. 
The real-time PCR analysis showed that COX-2 inducer TPA caused a considerable increase 
up to 9-fold in ABCG2 mRNA expression in parental MCF-7 cells (Fig. 2). While a slight 
increase in ABCG2 expression was observed in the resistant cell line MCF-7/MX. The results 
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of flow cytometry showed a slight increase of ABCG2 expression at protein level in MCF-7, 
while no significant changes in the level of ABCG2 protein expression was observed in 
MCF-7/MX (Fig. 3). As we mentioned earlier, in the drug resistant MCF-7/MX cells, ABCG2 
is already overexpressed, and its expression may be at a threshold maximum level, so an 
induction with TPA treatment may not be causing any detectable increase in ABCG2 mRNA 
level. Likewise, a close association between MDR and COX-2 has been reported in non-
Hodgkin's lymphomas (Szczuraszek et al., 2009), non-small cell lung cancer (Surowiak et al., 
2008) and breast cancer cases (Surowiak et al., 2005). Adenovirus-mediated transfer of rat 
COX-2 cDNA into renal rat mesangial cells increased P-glycoprotein (P-gp/MDR1) 
expression, and this was blocked by COX-2 inhibitor NS398, suggesting that COX-2 
products may be implicated in this response (Miller et al., 2006; Patel et al., 2002). All of 
these studies strongly suggest that COX-2 could be involved in the development of the MDR 





Fig. 3. Effect of TPA on ABCG2 protein levels in MCF-7 (A) and MCF-7/MX (B) cells. After 
48 h incubation with TPA (10 nM), expression of ABCG2 protein was measured by flow 
cytometry. Each histogram shows the overlay of the treated sample (dark gray), untreated 
sample (black) and secondary antibody as negative control (light gray). 
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Different studies showed that incubation of MDR cells with PKC activator TPA stimulate P-
gp phosphorylation, reduce drug accumulation, and enhance drug resistance 
(Ramachandran et al., 1998). Fine et al. demonstrated that phorbol 12,13-dibutyrate 
[P(BtO)2] led to an increase in protein kinase C activity and induced a drug-resistance 
phenotype as a result of increased phosphorylation of an unknown 20-kDa particulate 
protein (Fine et al., 1988). Similar to TPA treatment, diacylglycerol (DAG), a physiological 
stimulant of PKC, also increased the expression of MDR1 mRNA and protein. Whereas, 
protein kinase inhibitor staurosporine suppressed the induction of MDR1 expression by 
TPA and DAG (Chaudhary et al., 1992). These reports suggest that MDR gene expression in 
different cell types is regulated by a PKC-mediated pathway.  
ABCG2 function was measured by flow cytometric mitoxantrone efflux assay. In long term 
exposure TPA enhanced the ABCG2 function, which was more considerable in MCF-7/MX 
than parental MCF-7 cells (Kalalinia et al., 2010). There is considerable precedent that PKC 
activation is associated with increased transport processes. Fine et al showed that, protein 
kinase C activity was 7-fold higher in the drug-resistant mutant MCF-7 cells compared with 
the control MCF-7 cells, sensitive parent cells (Fine et al., 1988). Fine et al reported that 
exposure of drug-sensitive cells to the phorbol 12, 13-dibutyrate [P (BtO)2] caused an 
enhanced PKC activity and induced drug-resistance phenotype, whereas drug-resistant cells 
in the same exposure to P(BtO)2 showed further increased in drug resistance. So phorbol 
ester might be the reason of decreased drug accumulation by inducing phosphorylation of a 
drug efflux pump or carrier protein (Fine et al., 1988).  
2.3 Celecoxib (a selective inhibitor of COX-2) and ABCG2 expression and function  
Numerous studies showed that COX-2 inhibitors (coxibs) enhance the efficacy of different 
anticancer therapy methods. Different mechanisms have been suggested to contribute to the 
antitumor activity of coxibs such as the inhibition of cell cycle progression, induction of 
apoptosis, inhibition of angiogenesis and decreased invasive potential of tumor cells (Fife et 
al., 2004; Gasparini et al., 2003; Hashitani et al., 2003; Masferrer et al., 2000). Another 
mechanism by which COX-inhibitors could sensitize cells to chemotherapeutic drugs is 
functional blockade of membrane transporter proteins of the ABC-transporter family (Patel 
et al., 2002; Zatelli et al., 2005).  
Kalalinia et. al. investigated the relationship between the inhibition of COX-2 and 
expression of ABCG2 in parental and resistance breast cancer cell lines. They reported that 
treatment of MCF-7 and MCF-7/MX cells with celecoxib up-regulates ABCG2 expression at 
mRNA levels. The results also indicated that, celecoxib reversed the inhibitory effects of 
TPA on ABCG2 protein expression and increased its expression to the basal level in MCF-
7/MX, while co-treatment of MCF-7 cells with TPA and celecoxib caused increased ABCG2 
protein expression to a small amount more than TPA lonely (Fig. 4 ). In the same way , 
Zrieki et al. showed that treatment of human colorectal Caco-2 cell line with COX-1/ COX-2 
inhibitor naproxen led to an stimulation of ABCG2 expression which corresponded to the 
significant decrease of Rho123 retention achieved in activity study. In contrast, treatment 
with selective COX-2 inhibitors nimesulide did not influence the expression of ABCG2 at 
protein level (Zrieki et al., 2008). Several studies have shown that specific COX-2 inhibitors 
could prevent or reduce the development of chemoresistance phenotype by downregulation 
of the expression and function of P-glycoprotein (MDR1) (Huang et al., 2007; Kim et al., 
2004; Roy et al., 2010; Zatelli et al., 2005; Zatelli et al., 2007). Xia et al. found that celecoxib 
significantly inhibited MDR1 expression without any effects on pump function of P-gp. 
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They demonstrated that the inhibitory effect of celecoxib on MDR1 was COX-2-independent 
but directly correlated to hypermethylation of MDR1 gene promoter (Xia et al., 2009). In 
addition, it is shown that COX-2 inhibitors induced PGH2 generation and NF-κB activation, 





Fig. 4. Effects of celecoxib on the expression of ABCG2 at protein levels in MCF-7 (A) and 
MCF-7/MX (B) cell lines were studied by flow cytometry.  
Cells were fixed and permeabilized by formaldehyde and methanol, blocked with BSA and 
then incubated with primary monoclonal antibody BXP-21. After washing, cells were 
incubated with a FITC-conjugated goat anti-mouse antibody. Each histogram shows the 
overlay of the TPA treated sample (black), TPA and celecoxib treated sample (dark gray), 
untreated sample (ligh gray) and secondary antibody as negative control (broken light gray). 
In MCF-7 cell line, celecoxib in presence of TPA 10 nM caused reduction of ABCG2 function 
in a dose- and time-dependent manner (Kalalinia et al., 2010). Another study provides 
evidence that NS-398, selective COX-2 inhibitor, sensitizes chemoresistant breast cancer cells 
to the cytotoxic effects of doxorubicin and notably enhances intracellular DOX accumulation 
and retention in vitro. It was shown that these effects depended on the inhibition of P-gp 
expression and function in both native and chemoresistant MCF-7 cells (Zatelli et al., 2007). 
2.4 The influence of indomethacin on ABCG2 expression and function  
Several preclinical and clinical trials have shown that nonsteroidal anti-inflammatory drugs 
(NSAIDs), used as classical COX inhibitors, could reduce the incidence of cancers (Cha et al., 
2007; Kang et al., 2005; Lin et al., 2005). Although the exact anticancer mechanisms of 
NSAIDs are not fully understood, it seems to be related closely to their suppression of COX 
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enzyme and subsequent reduction in prostaglandin production (Kismet et al., 2004; Zatelli 
et al., 2005). Modulation of the efficacy of cancer chemotherapy by NSAIDs has not been 
examined in detail.  
Elahian et. al. investigated the pharmacological silencing of ABCG2 in MCF-7 cells through 
the use of indomethacin, in the hopes of opening a novel way in management of breast 
cancer. MTT assay showed that indomethacin did not significantly change the survival of 
MCF-7 and MCF-7/MX cells, but cotreatment of mitoxantrone with indomethacin increased 
the mitoxantrone cytotoxicity and reduced the IC50 of mitoxantrone in these cells. Altough 
indomethacin sensitized MCF-7 cells to mitoxantrone, but it did not alter mitoxantrone 
accumulation in MCF-7 cells, compared to the control (Elahian et al., 2010). It might suggest 
that indomethacin exerts the sensitising effects through a mechanism not involving the 
inhibition of ABCG2, but possibly reducing the synthesis of COX and its end-products 
(Spugnini et al., 2006; Verdina et al., 2008). Indeed, further studies would be necessary to 
clarify the molecular mechanisms involved in the potentiation of mitoxantrone cytotoxicity 
by indomethacin in MCF-7 and MCF-7/MX cells. Real-time PCR results showed that 
indomethacin-treated MCF-7 cells indicated no significant change in the amount of ABCG2 
mRNA expression. This observation has been also confirmed on the level of ABCG2 protein 
expression (Elahian et al., 2009). As a result, expression of a MDR phenotype in human 
malignant cells may not always be sensitive to potentiation of drug cytotoxicity by NSAIDs 
(Roller et al., 1999). The present results also confirmed other studies that show NSAIDs' 
effects are cell and efflux transporter specific (Nozaki et al., 2007). 
2.5 The influence of dexamethasone on ABCG2 expression and function  
Glucocorticoides are efficacious in the reducing of chemotherapy adverse side effects and 
show their intrinsic anticancer activity (Vee et al., 2009) (Pavek et al., 2005). Some 
glucocorticoids, such as beclomethasone, 6ǂ-methylprednisolone, dexamethasone, and 
triamcinolone, at micromolar concentrations, are shown to efficiently decrease the transport 
of ABCG2 substrates (Pavek et al., 2005).  
Glucocorticoide receptor agonists regulate gene expression in various ways, at the 
transcriptional (Adcock, 2001), posttranscriptional (Korhonen et al., 2002), and 
posttranslational levels (Kritsch et al., 2002). Direct interaction of ligand-activated GR with 
control elements of target genes could regulate gene transcription in a positive or negative 
way. However, there are different mechanisms for the negative regulation of gene 
transcription by glucocorticoides. They could interfere with general transcription factors 
such as activator protein-1 (AP-1) (Herrlich, 2001) and nuclear factor-κB (NF-κB) (Almawi et 
al., 2002), resulting in decreased transcription of AP-1- and NF-κB -responsive genes. 
Genomic organization of the ABCG2 gene revealed the presence of several AP-1 sites in the 
ABCG2 promoter (Bailey-Dell et al., 2001). So it could be a direct target of transcriptional 
repression in a similar way. On the other hand, it has been reported that dexamethasone 
mediates negative regulation of gene expression by destabilizing the mRNA of some target 
genes (Garcia-Gras et al., 2000; Lasa et al., 2002). 
Investigating the effects of dexamethasone on ABCG2 expression in MCF-7 cells showed 
that dexamethasone decreased the mRNA level of ABCG2 gene in comparison with control 
in MCF-7 and MCF-7/MX cell lines. Flow cytometry analysis indicated that a decrease in the 
level of ABCG2 protein was observed in dexamethasone treated MCF-7/MX cells. While the 
level of ABCG2 protein expressed as a ratio of the corresponding control was unchanged in 
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MCF-7 treated cells (Elahian et al., 2009). Cotreatment with different concentrations of 
mitoxantrone and dexamethasone increased the sensitivity of MCF-7 and MCF-7/MX cells 
to the toxic effects of mitoxantrone. In addition, the flow cytometry results showed that 
dexamethasone could inhibit the efflux and consequently caused increase in the 
accumulation of mitoxantrone in MCF-7/MX cells. However, ABCG2 inhibition by 
dexamethasone was not significant in MCF-7 cells (Elahian et al., 2010). 
These studies also confirmed that suppression role of dexamethasone on ABCG2 expression 
in MCF-7/MX cells was more significant than MCF-7 cells. It could be a confirmation for 
higher level of ABCG2 in MCF-7/MX cells compared with their parental cells and also 
confirmed other studies that show hormonal regulation of MDR gene expression is cell type 
specific (Demeule et al., 1999; Imai et al., 2005). 
3. Conclusion 
In this review we aimed to focuse on the explanation the role of inflammation on the 
ABCG2 expression and function, using MCF-7 human breast carcinoma cell line. Pro-
inflammatory cytokines have been found to be present within the micro-environment of 
tumors and inflammation. They are able to modulate the expression and function of 
different drug transporters. Mosaffa et al. showed that that proinflammatory cytokines IL-1ǃ 
and TNF-ǂ induce ABCG2 mRNA and protein expression and increase its function in MCF-
7 cells. In MCF-7/MX, these cytokines increased ABCG2 protein expression and function, 
but they have no influence on the transporter mRNA levels.  
Cyclooxygenase-2 (COX-2) is induced by mitogenic and inflammatory stimuli such as 
growth factors and cytokines, which results in enhanced synthesis of PGs in neoplastic and 
inflamed tissues. Kalalinia et al. studies had aimed to explore the potential link between 
COX-2 expression and development of multidrug resistance phenotype in MCF-7 cell line. 
They reported that COX-2 inducer TPA (12-O-tetradecanoylphorbol-13-acetate) caused a 
considerable increase up to 9-fold in ABCG2 mRNA expression in parental MCF-7 cells, 
while a slight increase in ABCG2 expression was observed in the resistant cell line MCF-
7/MX. They also showed a positive corrolation between ABCG2 protein expression and 
COX-2 protein level in each cell line. On the other hand, celecoxib (a selective inhibitor of 
COX-2) up-regulated the expression of ABCG2 mRNA in MCF-7 and MCF-7/MX cells, 
which was accompanied by increased ABCG2 protein expression. Furthermore, TPA could 
increase ABCG2 function in all cell lines with the greatest stimulatory effects in MCF-7/MX 
(more than 6 times the control level). In addition, celecoxib inverted the effects of TPA on 
ABCG2 function. This effect was more obvious in MCF-7/MX.  
Several studies have demonstrated that anti-inflammatory drugs like NSAIDs and some 
glucocorticoids could be effective in chemosensitizing of the many carcinoma cell lines to 
cytotoxic agents. The pharmacological modulation of ABCG2 in MCF-7 cells by 
dexamethasone and indomethacin was investigated by elahian et al. . They showed that 
dexamethasone induced downregulation of ABCG2 mRNA compared to controls in both 
MCF-7 and MCF-7/MX cell lines, whereas no changes were noted in the presence of 
indomethacin. The level of ABCG2 protein was decreased in dexamethasone treated MCF-
7/MX cells. Cotreatment of mitoxantrone with different concentrations of dexamethasone 
and indomethacin sensitized parental and resistant MCF-7 cells to mitoxantrone 
cytotoxicity. Dexamethasone also increased the accumulation of mitoxantrone in the MCF-
7/MX cell line, indicating an inhibitiory effect on the ABCG2 protein.  
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In this review, we describe the effects of proinflammatory cytokines (IL-1ǃ and TNF-ǂ), 
inflammatory mediator (COX-2) and anti-inflammatory drugs (celecoxib and 
dexametashone) on the expression of ABCG2 which addressed concerning to finding a new 
adjutant therapy for patients with cancer experiencing resistance to cancer treatment.  
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